title: Outcome of subsequent pregnancy after treatment for persistent gestational trophoblastic tumour.
abstract: BACKGROUND
  This study analysed subsequent pregnancy outcome in patients treated for persistent gestational trophoblastic tumour (GTT).
  
  
  METHODS
  Between 1974 and 1999, a total of 378 patients with GTT (83 patients with high-risk and 295 patients with low-risk GTT) were treated at Chiba University Hospital, Japan. Of these 378 patients, 363 (96.0%) achieved primary remission and 315 survivors have been followed at our hospital.
  
  
  RESULTS
  To date, 129 patients have had 243 subsequent conceptions. While pregnancy outcome was comparable with that of the general Japanese population, the incidence of repeat molar pregnancy (2.1%) was approximately seven times higher than that of the general population. During the mandatory HCG follow-up period of 1 year, 15 patients conceived within 6 months of completion of chemotherapy. The incidence of spontaneous abortion in these 15 patients was significantly higher than that in patients who conceived after a waiting period of >6 months (P = 0.0053).
  
  
  CONCLUSIONS
  Patients treated for GTT may anticipate a normal future reproductive outcome, although it would be better to avoid pregnancy for at least 6 months after completion of chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. matsui.heyte@cnc1.wakwak.com
authors.forename: Hideo
authors.initials: H
authors.lastname: Matsui
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Iitsuka
authors.forename: Kiyomi
authors.initials: K
authors.lastname: Suzuka
authors.forename: Koji
authors.initials: K
authors.lastname: Yamazawa
authors.forename: Katsuyoshi
authors.initials: K
authors.lastname: Seki
authors.forename: Souei
authors.initials: S
authors.lastname: Sekiya
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000188:drug therapy* / Q000453:epidemiology; D015994:Incidence; D011247:Pregnancy; D011256:Pregnancy Outcome; D012008:Recurrence; D014594:Uterine Neoplasms / Q000188:drug therapy*